NCT05469178 2025-10-29
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
BerGenBio ASA
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
NCT02424617 2025-02-26
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
BerGenBio ASA
Phase 1/2 Completed
NCT06469138 2025-01-29
8479217
BerGenBio ASA
Phase 1 Completed
NCT02922777 2024-02-21
Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT03649321 2023-11-09
Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT03824080 2021-12-21
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes
GWT-TUD GmbH
Phase 2 Completed
NCT03184558 2021-11-09
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
BerGenBio ASA
Phase 2 Terminated